• (+5411) 3965-8409
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

HPTN 083

HPTN 083 clinical trial

The HPTN 083 clinical trial are prove to have  that a pre-exposure prophylaxis (PrEP) regime containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men. Both cabotegravir and oral tenofovir/emtricitabine (TDF/FTC) shown to have high efficacy for pre-exposure prophylaxis (PrEP)

Mas info: https://www.hptn.org/



Urquiza 358, Balvanera (CP 1215).
Ciudad Autónoma de Buenos Aires, Argentina

Tel.: (+5411) 3965-8409

A nonprofit project of


© 2023 CICAL. Todos los derechos reservados.